Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 1/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963276 | 0.93 | CPT1A (0.58) | CPT1ACPT1BP2RY14SMN1; SMN2MEN1 | |
| SCHEMBL957803 | 0.90 | CPT1A (0.58) | CPT1ACPT1BP2RY14PTGER4ENPP2 | |
| SCHEMBL961299 | 0.84 | P2RY14 (0.48) | CPT1ACPT1BP2RY14SMN1; SMN2MEN1 | |
| SCHEMBL957619 | 0.82 | CPT1A (0.68) | CPT1ACPT1BP2RY14PTGER4ENPP2 | |
| SCHEMBL959354 | 0.82 | CPT1A (0.60) | CPT1ACPT1BP2RY14SMN1; SMN2PTGER4 | |
| SCHEMBL963616 | 0.80 | SMN1; SMN2 (0.56) | CPT1ACPT1BSMN1; SMN2MEN1KMT2A | |
| SCHEMBL959029 | 0.80 | CPT1A (0.55) | CPT1ACPT1BP2RY14SMN1; SMN2ALDH1A1 | |
| SCHEMBL962045 | 0.76 | CPT1A (0.83) | CPT1ACPT1BP2RY14SMN1; SMN2MEN1 | |
| SCHEMBL958234 | 0.75 | FSCN1 (0.58) | CPT1ACPT1BSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20079499 | 0.74 | ENPP2 (0.52) | MEN1KMT2APTGER4MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | disclosed |
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885P2RY14 1643/4885 |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885P2RY14 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.